Evidence map›Paper›PMID 30106598›Full record

ArticleThe journal of histochemistry and cytochemistry : official journal of the Histochemistry Society2018

4',6-Diamidino-2-Phenylindole Distinctly Labels Tau Deposits.

Chengyu Li, Tetsuya Takahashi, Tejashwi Shrestha, Eiji Kinoshita, Tomoyasu Matsubara, Masayasu Matsumoto, Hirofumi Maruyama

Open access · bronzeAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
0.1field-weighted citation impact, top 51% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 4 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 1 institution in 1 country.

Chengyu LiDepartment of Clinical Neuroscience and Therapeutics, Graduate School of Biomedical & Health Sciences, Hiroshima University, Hiroshima, Japan.
Tetsuya TakahashiDepartment of Clinical Neuroscience and Therapeutics, Graduate School of Biomedical & Health Sciences, Hiroshima University, Hiroshima, Japan.
Tejashwi ShresthaDepartment of Clinical Neuroscience and Therapeutics, Graduate School of Biomedical & Health Sciences, Hiroshima University, Hiroshima, Japan.
Eiji KinoshitaDepartment of Functional Molecular Science, Graduate School of Biomedical & Health Sciences, Hiroshima University, Hiroshima, Japan.
Tomoyasu MatsubaraDepartment of Clinical Neuroscience and Therapeutics, Graduate School of Biomedical & Health Sciences, Hiroshima University, Hiroshima, Japan.
Masayasu MatsumotoDepartment of Clinical Neuroscience and Therapeutics, Graduate School of Biomedical & Health Sciences, Hiroshima University, Hiroshima, Japan.
Hirofumi MaruyamaDepartment of Clinical Neuroscience and Therapeutics, Graduate School of Biomedical & Health Sciences, Hiroshima University, Hiroshima, Japan.ORCID 0000-0001-7613-8717
Hiroshima University · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Tau deposits have distinct biochemical characteristics and vary morphologically based on identification with tau antibodies and several chemical dyes. Here, we report 4',6-diamidino-2-phenylindole (DAPI)-positivity of tau deposits. Furthermore, we investigated the cause for this positivity. DAPI was positive in 3R/4R (3-repeat/4-repeat) tau deposits in Alzheimer's disease, myotonic dystrophy, and neurodegeneration with brain iron accumulation, and in 4R tau deposits in corticobasal degeneration, but negative in 4R tau deposits in frontotemporal dementia with parkinsonism-17 and progressive supranuclear palsy. The peak emission wavelength of DAPI after binding to a tau deposit was similar to that after binding to a nucleus. This DAPI-positivity was conspicuous at the optimum concentration of 2 μg/ml. DAPI-positivity was diminished after formic acid treatment, but preserved after nucleic acid elimination and phosphate moiety blocking. Our results suggest that staining with 2 μg/ml DAPI is a common but useful tool to differentially detect tau deposits in various tauopathies.

Indexed as

AgedAged, 80 and overAlzheimer DiseaseBrainFluorescent DyesFrontotemporal DementiaHumansIndolesMaleMiddle AgedMyotonic DystrophyParkinson DiseaseProtein IsoformsStaining and LabelingSupranuclear Palsy, ProgressiveTauopathiesDAPIFluorescent DyesIndolesProtein Isoformstau Proteins4′,6-diamidino-2-phenylindoleneurofibrillary tanglePhos-tagtauopathies

Identifiers

PMID30106598
PMCPMC6158628
OpenAlexW2772497116

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.